The German drug giant Schering halted its development program in 2006,
and other drug companies quickly followed suit, abandoning several projects that were on the verge of success.
Major pharmaceutical companies like Wyeth, Schering and Organon were pumping millions into male
hormonal birth-control drug discovery, but they concluded that there wasn't enough of a market to make male hormonal contraceptives worthwhile.